RxDoctor Payments Data

Steven Atkins, MD

Neurology · Marrero, LANPI 1245276336

Payments from drug & device makers

$9,388in general payments, 2019–2025

Across 566 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Acadia Pharmaceuticals Inc$803
  • Amgen$493
  • Ipsen Biopharmaceuticals, Inc$400
  • Argenx US, Inc.$399
  • plus $5K from 43 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$9,364100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,388 in reported general payments places this provider in the 65th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$68,366
Medicare patients
249
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5048$548,797
GocovriAmantadine Hcl44$94,966
CopaxoneGlatiramer Acetate12$69,984
UbrelvyUbrogepant49$65,719
Nurtec OdtRimegepant Sulfate46$63,433
QuliptaAtogepant29$39,511
VimpatLacosamide33$30,759
Aimovig AutoinjectorErenumab-Aooe41$30,372
TrileptalOxcarbazepine23$28,146
RexultiBrexpiprazole12$17,857
NeuproRotigotine11$9,449
Carbidopa-Levodopa ErCarbidopa/Levodopa191$8,764
Emgality PenGalcanezumab-Gnlm11$7,777
Lacosamide134$7,540
Levetiracetam317$6,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$94$548,79748 claims
AbbVieUbrelvy, Qulipta$1,614$105,23078 claims
MDD US Operations, LLCGocovri$295$94,96644 claims
Teva Pharmaceuticals USA, Inc.Copaxone$153$69,98412 claims
PfizerNurtec Odt$277$63,43346 claims
UCB, Inc.Vimpat, Neupro$1,077$40,20744 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$17,85712 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$17$5,93197 claims
Upsher-smith Laboratories LLCTopiramate$27$3,763194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 225 neurology providers in Louisiana.

Other neurology in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →